PD1/CTLA4 binders

US10544222B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Juha Punnonen · Belmont, US
• Edward Bowman · Redwood City, US
• Maribel Beaumont · San Mateo, US
• Marie-Ange Buyse · Merelbeke, BE
• Carlo Boutton · Wielsbeke, BE
• Bruno Dombrecht · Heusden, BE
• Bjorn Victor · Zwijndrecht, BE
• David Vlerick · Gentbrugge, BE
• Robert A. Kastelein · Portola Valley, US

Key dates

• Filing date: Nov 17, 2016
• Grant date: Jan 28, 2020
• Expiry date: Oct 8, 2037

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides multispecific molecules, e.g., comprising more than one ISVD or Nanobody, that bind to PD1 and CTLA4. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.